

Change in Boardroom

IHH HEALTHCARE BERHAD

Date of change	01 Jan 2020
Name	DR KELVIN LOH CHI-KEON
Age	46
Gender	Male
Nationality	Singapore
Type of change	Redesignation
Previous Position	Executive Director
New Position	Managing Director
Directorate	Executive

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Masters	Business Administration	National University of Singapore Business School	
2	Degree	Bachelor of Medicine and Bachelor of Surgery	National University of Singapore	

Working experience and occupation

Dr Kelvin Loh Chi-Keon ("Dr Kelvin Loh") joined IHH Healthcare Berhad ("IHH") on 1 July 2019 as Chief Executive Officer ("CEO") (designate) and Executive Director from Columbia Asia Group where he was CEO. Presently, he also serves on the Boards and Board Committees of IHH subsidiaries, namely Parkway Pantai Limited, Fortis Healthcare Limited, SRL Limited and Acibadem Saglik Yatirimlari Holding A.S. Group. Dr Kelvin Loh started his career as a practicing physician before serving for 10 years in the public sector in Singapore, in areas such as clinical services development, hospital planning and hospital operations.

Dr Kelvin Loh previously joined the IHH Group in 2008, and between 2008 and 2017 held a number of senior management roles, before taking over as CEO for the Singapore Operations Division, covering among other services, the 4 multi-specialty tertiary hospitals - Mount Elizabeth, Mount Elizabeth Novena, Gleneagles and Parkway East.

Dr Kelvin Loh moved to Columbia Asia Group as CEO in 2017 where he was responsible for overseeing Columbia Asia Group's 28 hospitals across 4 countries in Asia including Malaysia and India.

Dr Kelvin Loh is a senior healthcare executive with strong track record of delivery. He has extensive experience in leading large healthcare businesses, building relationships with stakeholders, managing hospital operations, financial management and developing people. He is also deeply familiar with the healthcare operating context in diverse countries across Asia.

Family relationship with any director and/or major shareholder of the listed issuer

Nil

Any conflict of interests that he/she has with the listed issuer

Nil

Details of any interest in the

Dr Kelvin Loh's interest as at 31 December 2019 is as follows:

... of any interest in the securities of the listed issuer or its subsidiaries

Direct interest in a subsidiary:
Parkway Life Real Estate Investment Trust - 120,000 units

Remarks :
Reference is made to the announcement dated 27 May 2019 bearing reference no. C03-27052019-00002. Dr Kelvin Loh will assume the position of Managing Director and Chief Executive Officer of IHH with effect from 1 January 2020, to succeed Dr Tan See Leng upon the completion of his contract period on 31 December 2019.

Announcement Info	
Company Name	IHH HEALTHCARE BERHAD
Stock Name	IHH
Date Announced	31 Dec 2019
Category	Change in Boardroom
Reference Number	C03-31122019-00008